“…In the process of chiral discrimination, the functional groups in the molecular receptor preferentially interact with one of the enantiomers in the chiral molecule based on a noncovalent interaction, such as hydrogen bonding, electrostatic interaction, or hydrophobic interaction. 1 In many cases, while one enantiomer exhibits desirable physiological, pharmacological, pharmacodynamic, and pharmacokinetic properties, the other enantiomer can display toxicity towards living organisms and a different activity in chemical or biotechnological processes. Therefore, replacing the racemic form with a single-enantiomeric form in the drug market has * Author to whom correspondence should be addressed.…”